Market Closed -
OTC Markets
20:59:30 14/06/2024 BST
|
5-day change
|
1st Jan Change
|
16.55
USD
|
-1.43%
|
|
+1.41%
|
-23.91%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
12,844
|
14,460
|
18,352
|
15,573
|
16,747
|
12,173
|
-
|
-
|
Enterprise Value (EV)
1 |
15,143
|
17,845
|
20,687
|
16,370
|
19,049
|
14,893
|
14,837
|
14,725
|
P/E ratio
|
22.2
x
|
27.5
x
|
14.1
x
|
10.9
x
|
24.5
x
|
24.6
x
|
21.7
x
|
18.7
x
|
Yield
|
3.1%
|
2.79%
|
2.37%
|
3.03%
|
2.92%
|
3.72%
|
3.8%
|
4.08%
|
Capitalization / Revenue
|
2.09
x
|
2.12
x
|
2.1
x
|
1.67
x
|
2.05
x
|
1.38
x
|
1.3
x
|
1.25
x
|
EV / Revenue
|
2.47
x
|
2.61
x
|
2.36
x
|
1.75
x
|
2.33
x
|
1.68
x
|
1.58
x
|
1.51
x
|
EV / EBITDA
|
14.3
x
|
12.5
x
|
8.08
x
|
5.78
x
|
11.2
x
|
9.31
x
|
8.6
x
|
7.88
x
|
EV / FCF
|
26.8
x
|
15.9
x
|
11.7
x
|
8.44
x
|
17.6
x
|
21.4
x
|
17.5
x
|
15.7
x
|
FCF Yield
|
3.74%
|
6.31%
|
8.55%
|
11.8%
|
5.68%
|
4.67%
|
5.7%
|
6.38%
|
Price to Book
|
2.37
x
|
2.55
x
|
2.87
x
|
2.14
x
|
2.17
x
|
1.54
x
|
1.53
x
|
1.5
x
|
Nbr of stocks (in thousands)
|
473,945
|
475,174
|
477,907
|
471,771
|
470,806
|
480,404
|
-
|
-
|
Reference price
2 |
27.10
|
30.43
|
38.40
|
33.01
|
35.57
|
25.34
|
25.34
|
25.34
|
Announcement Date
|
19/08/19
|
19/08/20
|
23/08/21
|
23/08/22
|
16/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6,134
|
6,832
|
8,752
|
9,340
|
8,169
|
8,840
|
9,368
|
9,757
|
EBITDA
1 |
1,061
|
1,425
|
2,560
|
2,830
|
1,708
|
1,600
|
1,725
|
1,868
|
EBIT
1 |
787.7
|
819.2
|
1,918
|
2,155
|
1,005
|
825.6
|
915.3
|
1,032
|
Operating Margin
|
12.84%
|
11.99%
|
21.92%
|
23.07%
|
12.3%
|
9.34%
|
9.77%
|
10.58%
|
Earnings before Tax (EBT)
1 |
722.3
|
699.1
|
1,829
|
2,077
|
931.2
|
698.2
|
785.3
|
923.1
|
Net income
1 |
549.7
|
527.7
|
1,315
|
1,461
|
685
|
492.7
|
561.5
|
651.1
|
Net margin
|
8.96%
|
7.72%
|
15.03%
|
15.64%
|
8.39%
|
5.57%
|
5.99%
|
6.67%
|
EPS
2 |
1.221
|
1.106
|
2.731
|
3.025
|
1.450
|
1.030
|
1.169
|
1.354
|
Free Cash Flow
1 |
565.7
|
1,125
|
1,769
|
1,939
|
1,082
|
694.8
|
846.1
|
939.7
|
FCF margin
|
9.22%
|
16.47%
|
20.22%
|
20.76%
|
13.24%
|
7.86%
|
9.03%
|
9.63%
|
FCF Conversion (EBITDA)
|
53.33%
|
78.97%
|
69.12%
|
68.5%
|
63.36%
|
43.42%
|
49.05%
|
50.3%
|
FCF Conversion (Net income)
|
102.91%
|
213.24%
|
134.54%
|
132.75%
|
157.95%
|
141.01%
|
150.69%
|
144.32%
|
Dividend per Share
2 |
0.8400
|
0.8500
|
0.9100
|
1.000
|
1.040
|
0.9427
|
0.9640
|
1.034
|
Announcement Date
|
19/08/19
|
19/08/20
|
23/08/21
|
23/08/22
|
16/08/23
|
-
|
-
|
-
|
Fiscal Period: June |
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 S1
|
2023 S2
|
2024 S1
|
2024 S2
|
2025 S1
|
2025 S2
|
---|
Net sales
1 |
3,344
|
3,488
|
4,432
|
4,319
|
4,757
|
4,584
|
4,082
|
4,087
|
4,306
|
4,625
|
4,592
|
4,847
|
EBITDA
1 |
548
|
877.1
|
1,307
|
1,253
|
1,540
|
1,291
|
920.2
|
787.3
|
736.7
|
867
|
811
|
902
|
EBIT
1 |
399.9
|
419.3
|
993.8
|
924.4
|
1,208
|
947
|
574.6
|
430
|
353
|
462
|
404
|
478
|
Operating Margin
|
11.96%
|
12.02%
|
22.42%
|
21.4%
|
25.39%
|
20.66%
|
14.07%
|
10.52%
|
8.2%
|
9.99%
|
8.8%
|
9.86%
|
Earnings before Tax (EBT)
1 |
347.4
|
-
|
944
|
884.6
|
1,168
|
908.7
|
536.9
|
394.3
|
300
|
389
|
326
|
402
|
Net income
1 |
256
|
271.7
|
677.6
|
637.4
|
827.7
|
632.9
|
382.4
|
302.6
|
202.3
|
273
|
220
|
282
|
Net margin
|
7.66%
|
7.79%
|
15.29%
|
14.76%
|
17.4%
|
13.81%
|
9.37%
|
7.41%
|
4.7%
|
5.9%
|
4.79%
|
5.82%
|
EPS
2 |
0.5370
|
0.5690
|
1.409
|
1.322
|
1.708
|
1.317
|
0.8090
|
0.6410
|
0.4260
|
0.5655
|
0.4695
|
0.5650
|
Dividend per Share
2 |
0.3400
|
0.5100
|
0.3600
|
0.5500
|
0.4000
|
0.6000
|
0.4200
|
0.6200
|
0.4300
|
0.6510
|
0.4520
|
0.6800
|
Announcement Date
|
18/02/20
|
19/08/20
|
17/02/21
|
23/08/21
|
20/02/22
|
23/08/22
|
15/02/23
|
16/08/23
|
19/02/24
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
2,299
|
3,386
|
2,335
|
797
|
2,302
|
2,719
|
2,663
|
2,551
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.167
x
|
2.376
x
|
0.9122
x
|
0.2816
x
|
1.348
x
|
1.7
x
|
1.544
x
|
1.366
x
|
Free Cash Flow
1 |
566
|
1,125
|
1,769
|
1,939
|
1,082
|
695
|
846
|
940
|
ROE (net income / shareholders' equity)
|
11.5%
|
9.46%
|
22%
|
21.4%
|
9.05%
|
6.21%
|
6.88%
|
7.88%
|
ROA (Net income/ Total Assets)
|
6.05%
|
4.78%
|
11%
|
12%
|
5.36%
|
3.81%
|
4.26%
|
4.81%
|
Assets
1 |
9,080
|
11,044
|
11,944
|
12,156
|
12,776
|
12,940
|
13,184
|
13,524
|
Book Value Per Share
2 |
11.40
|
11.90
|
13.40
|
15.40
|
16.40
|
16.50
|
16.60
|
16.90
|
Cash Flow per Share
2 |
1.880
|
2.850
|
4.240
|
4.610
|
3.110
|
2.300
|
2.680
|
2.910
|
Capex
1 |
282
|
235
|
274
|
287
|
389
|
500
|
517
|
549
|
Capex / Sales
|
4.59%
|
3.44%
|
3.13%
|
3.07%
|
4.76%
|
5.66%
|
5.52%
|
5.62%
|
Announcement Date
|
19/08/19
|
19/08/20
|
23/08/21
|
23/08/22
|
16/08/23
|
-
|
-
|
-
|
Last Close Price
25.34
AUD Average target price
27.3
AUD Spread / Average Target +7.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +68.16% | 4.32B | | +6.69% | 2.74B | | -2.98% | 2.6B | | -50.95% | 1.97B | | -18.54% | 1.68B | | -21.29% | 1.45B | | +16.69% | 1.2B | | -44.86% | 1.12B | | +17.43% | 975M |
Medical & Diagnostic Laboratories
|